Validation of new real‐time polymerase chain reaction assays for detection of hepatitis A virus RNA and parvovirus B19 DNA

Backer, Marijke W. A. Molenaar-de; Waal, Mirjam de; Sjerps, Margret; Koppelman, Marco

doi:10.1111/trf.13334

Cited by 19 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mean viral load detected in CKD patients from all dialysis units was 10 4 IU/mL. As reported in previous studies, this mean viral load could be linked to a risk of B19V transmission through blood components (Molenaar-de Backer et al, 2016a;Molenaar-de Backer et al, 2016b;use Cfmpfh, 2012).…”

Section: Discussionsupporting

confidence: 72%

High prevalence of parvovirus B19 infection in patients with chronic kidney disease under hemodialysis: A multicenter study

Alves

Langella

Barbosa

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Objectives: Parvovirus B19 (B19V) infection is commonly acute and self-limited, but in chronic kidney disease (CKD) patients under dialysis treatment, this infection could increase susceptibility to acute and chronic anemia. The aim of this study was to evaluate the frequency and risk of B19V infection among Brazilian CKD patients under dialysis. Methods: A study was conducted among 221 CKD patients and a control group of 142 blood donors. B19V infection was evaluated in serum samples by real-time PCR, and ELISA (anti-B19V IgM and IgG). Results: B19V DNA was detected in 65% (145/221) of CKD patients, which was significantly higher (p < 0.001) than in the blood donors (6.3%). Simultaneous detection of B19V IgG and viremia was shown in 40.3% of CKD patients, which was indicative of persistent B19V infection. CKD patients showed an increased risk of developing B19V infection (OR = 28.1, CI = 13.5-58.5, p = 0.001). Conclusions: Despite an absence of clinical signs of B19V infection, these data highlight the importance of B19V infection in this high-risk population, since a persistent B19V infection could become clinically significant after renal transplant. Moreover, the persistent viremia should be considered as a potential risk, mainly because of the contamination of dialysis equipment.

show abstract

Section: Discussionsupporting

confidence: 72%

High prevalence of parvovirus B19 infection in patients with chronic kidney disease under hemodialysis: A multicenter study

Alves

Langella

Barbosa

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…If the difference between two results from different laboratories exceeds R, the results must be considered suspect (Anonymous, 2009 ). The reproducibility is usually defined by collaborative studies, which determine the variability of the results obtained by the given method in different laboratories using identical samples (Anonymous, 2009 , 2012 ; Molenaar-de Backer et al, 2016 ). The number of laboratories with valid results which should be included in the collaborative study is at least eight.…”

Section: Qpcr Parameters In Microbial Detection and Quantificationmentioning

confidence: 99%

A Basic Guide to Real Time PCR in Microbial Diagnostics: Definitions, Parameters, and Everything

2017

View full text Add to dashboard Cite

Real time PCR (quantitative PCR, qPCR) is now a well-established method for the detection, quantification, and typing of different microbial agents in the areas of clinical and veterinary diagnostics and food safety. Although the concept of PCR is relatively simple, there are specific issues in qPCR that developers and users of this technology must bear in mind. These include the use of correct terminology and definitions, understanding of the principle of PCR, difficulties with interpretation and presentation of data, the limitations of qPCR in different areas of microbial diagnostics and parameters important for the description of qPCR performance. It is not our intention in this review to describe every single aspect of qPCR design, optimization, and validation; however, it is our hope that this basic guide will help to orient beginners and users of qPCR in the use of this powerful technique.

show abstract

“…This can be also done by minipools, in which multiple donations are brought together for NAT screening. Screening assays nowadays have a sufficient sensitivity ( 36 , 71 , 72 ) to reliably detect donations even with minimal amounts of B19V DNA. On the basis of the current knowledge, maximal security in terms of avoiding a TT-B19V infection is provided, if the sensitivity of the assay is sufficient to detect a single donation with a B19V DNA concentration of 10 3 IU B19V DNA/ml plasma.…”

Section: Conclusion: What Is the Relevance Of B19v In Transfusion Medmentioning

confidence: 99%

Parvovirus B19: What Is the Relevance in Transfusion Medicine?

Juhl¹,

Hennig²

2018

Front. Med.

View full text Add to dashboard Cite

Parvovirus B19 (B19V) has been discovered in 1975. The association with a disease was unclear in the first time after the discovery of B19V, but meanwhile, the usually droplet transmitted B19V is known as the infectious agent of the “fifth disease,” a rather harmless children’s illness. But B19V infects erythrocyte progenitor cells and thus, acute B19V infection in patients with a high erythrocyte turnover may lead to a life-threatening aplastic crisis, and acutely infected pregnant women can transmit B19V to their unborn child, resulting in a hydrops fetalis and fetal death. However, in many adults, B19V infection goes unnoticed and thus many blood donors donate blood despite the infection. The B19V infection does not impair the blood cell counts in healthy blood donors, but after the acute infection with extremely high DNA concentrations exceeding 1010 IU B19V DNA/ml plasma is resolved, B19V DNA persists in the plasma of blood donors at low levels for several years. That way, many consecutive donations that contain B19V DNA can be taken from a single donor, but the majority of blood products from donors with detectable B19V DNA seem not to be infectious for the recipients from several reasons: first, many recipients had undergone a B19V infection in the past and have formed protective antibodies. Second, B19V DNA concentration in the blood product is often too low to infect the recipient. Third, after the acute infection, the presence of B19V DNA in the donor is accompanied by presumably neutralizing antibodies which are protective also for the recipient of his blood products. Thus, transfusion-transmitted (TT-) B19V infections are very rarely reported. Moreover, in most blood donors, B19V DNA concentration is below 1,000 IU/ml plasma, and no TT-B19V infections have been found by such low-viremic donations. Cutoff for an assay for B19V DNA blood donor screening should, therefore, be approximately 1,000 IU/ml plasma, if a general screening of blood donors for single donation blood components is considered at all: for the overwhelming majority of transfusion recipients, B19V infection is not relevant as well as for the blood donors. B19V DNA screening of vulnerable patients after transfusion seems to be a more reasonable approach than general blood donor screening.

show abstract

Validation of new real‐time polymerase chain reaction assays for detection of hepatitis A virus RNA and parvovirus B19 DNA

Cited by 19 publications

References 30 publications

High prevalence of parvovirus B19 infection in patients with chronic kidney disease under hemodialysis: A multicenter study

High prevalence of parvovirus B19 infection in patients with chronic kidney disease under hemodialysis: A multicenter study

A Basic Guide to Real Time PCR in Microbial Diagnostics: Definitions, Parameters, and Everything

Parvovirus B19: What Is the Relevance in Transfusion Medicine?

Contact Info

Product

Resources

About